Directorate change Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 (“Mediclinic”, the “Company” or the “Group”) 15 November 2018 DIRECTORATE CHANGE The Company announces that on 14 November 2018, Mr Desmond Smith, the Company’s Senior Independent Director, informed the Board of his intention to retire as a director of the Company at the conclusion of the Company’s Annual General Meeting (“AGM”) scheduled for 24 July 2019 and not seek re-election at the AGM. Mr Smith will also step down from all Board committees at that time. Mr Alan Grieve will succeed Mr Smith as Senior Independent Director of the Company and as Chairman of the Audit and Risk Committee, to be effective from the date of Mr Smith’s resignation in 2019. Further changes to the constitution of the Company’s committees will be made and announced in due course. Mediclinic's chairman, Dr Edwin Hertzog commented: “On behalf of my colleagues on the Board, I would like to thank Desmond for his commitment and valued contributions to the Board and the Group over many years.” This announcement is made in accordance with the requirement of LR 9.6.11. About Mediclinic International plc Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group. Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden operates 18 private hospitals and 4 clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 4 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics with more than 900 inpatient beds in the United Arab Emirates. Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia. For further information, please contact: Company Secretary, Link Company Matters Limited Jayne Meacham / Caroline Emmet +44 (0)20 7954 9569 Investor Relations, Mediclinic International plc James Arnold, Head of Investor Relations ir@mediclinic.com +44 (0)20 3786 8181 Media queries FTI Consulting Brett Pollard/Debbie Scott – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited) NSX sponsor: Simonis Storm Securities (Pty) Ltd Date: 15/11/2018 09:01:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.